Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
Importance
Active monitoring for low-risk ductal carcinoma in situ (DCIS) of the breast has been proposed as an alternative to guideline-concordant care, but the safety of this approach is unknown.
Objective
To compare rates of invasive cancer in patients with low-risk DCIS receiving active monitoring vs guideline-concordant care.
Design, Setting, and Participants
Prospective, randomized noninferiority trial enrolling 995 women aged 40 years or older with a new diagnosis of hormone receptor–positive grade 1 or grade 2 DCIS without invasive cancer at 100 US Alliance Cancer Cooperative Group clinical trial sites from 2017 to 2023.
Interventions
Participants were randomized to receive active monitoring (follow-up every 6 months with breast imaging and physical examination; n = 484) or guideline-concordant care (surgery with or without radiation therapy; n = 473).
Main Outcomes and Measures
The primary outcome was 2-year cumulative risk of ipsilateral invasive cancer diagnosis, according to planned intention-to-treat and per-protocol analyses, with a noninferiority bound of 0.05%.
Results
The median age of the 957 participants analyzed was 63.6 (95% CI, 55.5-70.5) years in the guideline-concordant care group and 63.7 (95% CI, 60.0-71.6) years in the active monitoring group. Overall, 15.7% of participants were Black and 75.0% were White. In this prespecified primary analysis, median follow-up was 36.9 months; 346 patients had surgery for DCIS, 264 in the guideline-concordant care group and 82 in the active monitoring group. Forty-six women were diagnosed with invasive cancer, 19 in the active monitoring group and 27 in the guideline-concordant care group. The 2-year Kaplan-Meier cumulative rate of ipsilateral invasive cancer was 4.2% in the active monitoring group vs 5.9% in the guideline-concordant care group, a difference of −1.7% (upper limit of the 95% CI, 0.95%), indicating that active monitoring is not inferior to guideline-concordant care. Invasive tumor characteristics did not differ significantly between groups.
Conclusions and Relevance
Women with low-risk DCIS randomized to active monitoring did not have a higher rate of invasive cancer in the same breast at 2 years compared with those randomized to guideline-concordant care.
Trial Registration
ClinicalTrials.gov Identifier:
Top-30
Journals
|
1
2
3
4
|
|
|
JAMA - Journal of the American Medical Association
4 publications, 10.26%
|
|
|
Annals of Surgical Oncology
4 publications, 10.26%
|
|
|
Breast Cancer Research and Treatment
3 publications, 7.69%
|
|
|
Cancers
2 publications, 5.13%
|
|
|
BMJ
2 publications, 5.13%
|
|
|
Breast Care
2 publications, 5.13%
|
|
|
The Lancet Digital Health
1 publication, 2.56%
|
|
|
Oncology Times
1 publication, 2.56%
|
|
|
JAMA Oncology
1 publication, 2.56%
|
|
|
Oncotarget
1 publication, 2.56%
|
|
|
Breast
1 publication, 2.56%
|
|
|
Statistical Theory and Related Fields
1 publication, 2.56%
|
|
|
Nature Reviews Clinical Oncology
1 publication, 2.56%
|
|
|
International Journal of Radiation Oncology Biology Physics
1 publication, 2.56%
|
|
|
International Journal of Epidemiology
1 publication, 2.56%
|
|
|
World Journal of Surgical Oncology
1 publication, 2.56%
|
|
|
Health Communication
1 publication, 2.56%
|
|
|
Radiographics
1 publication, 2.56%
|
|
|
JAMA Dermatology
1 publication, 2.56%
|
|
|
Breast Cancer Research
1 publication, 2.56%
|
|
|
Health Promotion International
1 publication, 2.56%
|
|
|
Menopause
1 publication, 2.56%
|
|
|
Histopathology
1 publication, 2.56%
|
|
|
Annals of Oncology
1 publication, 2.56%
|
|
|
Frontiers in Oncology
1 publication, 2.56%
|
|
|
Biomedicines
1 publication, 2.56%
|
|
|
Value in Health
1 publication, 2.56%
|
|
|
Surgery (US)
1 publication, 2.56%
|
|
|
1
2
3
4
|
Publishers
|
2
4
6
8
10
|
|
|
Springer Nature
10 publications, 25.64%
|
|
|
American Medical Association (AMA)
6 publications, 15.38%
|
|
|
Elsevier
6 publications, 15.38%
|
|
|
MDPI
3 publications, 7.69%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 5.13%
|
|
|
Taylor & Francis
2 publications, 5.13%
|
|
|
BMJ
2 publications, 5.13%
|
|
|
Oxford University Press
2 publications, 5.13%
|
|
|
S. Karger AG
2 publications, 5.13%
|
|
|
Impact Journals
1 publication, 2.56%
|
|
|
Radiological Society of North America (RSNA)
1 publication, 2.56%
|
|
|
Wiley
1 publication, 2.56%
|
|
|
Frontiers Media S.A.
1 publication, 2.56%
|
|
|
2
4
6
8
10
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.